- Eculizumab, sold
under the
brand name
Soliris among others, is a
recombinant humanized monoclonal antibody used to
treat paroxysmal nocturnal hemoglobinuria...
-
orphan drugs to
treat rare diseases. Its
products include eculizumab (
Soliris) and
ravulizumab (Ultomiris), both used to
treat the rare
disorders of...
-
hemolysis in
people treated with
eculizumab (
Soliris). The
highest risk was when
individuals "received a dose of
Soliris within 2 w****s
after being vaccinated...
- anti–factor H antibodies.: 1933
Prior to
availability of
eculizumab (
Soliris) and
ravulizumab (Ultomiris), an
estimated 33–40% of
patients died or developed...
-
continued long-term
after an
episode of thrombosis. In 2007,
eculizumab (
Soliris) was
approved for the
treatment of PNH.
Prior to eculizumab, the median...
-
Bernie (April 14, 2023). "Alexion Will Face
Securities class Action Over
Soliris Sales". news.bloomberglaw.com.
Retrieved February 2, 2024. Nilsson, Henrik...
-
antibodies patients with aHUS had an
extremely poor prognosis.
Eculizumab (
Soliris®,
Alexion Pharmaceuticals, Inc., Boston, MA, USA) is a
humanized monoclonal...
- (brand)
Brand Date of FDA
approval Mechanism of
action Note
Eculizumab Soliris 2019
Monoclonal antibody against complement protein C5
Approved for AQP4-IgG-positive...
-
Ecromeximab mab
chimeric GD3
ganglioside malignant melanoma Eculizumab Soliris mab
humanized C5 Y
paroxysmal nocturnal hemoglobinuria,
atypical hemolytic...
-
intravenous fully human PD-L1
Urothelial carcinoma 761069 Link
eculizumab Soliris Alexion 3/16/2007
intravenous humanized Complement component 5 Paroxysmal...
